menu
    • menu
    [{"orgOrder":0,"company":"Ubiquigent","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ubiquigent","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ubiquigent \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Ubiquigent \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ubiquigent","sponsor":"Medivir","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ubiquigent","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ubiquigent \/ Ubiquigent","highestDevelopmentStatusID":"4","companyTruncated":"Ubiquigent \/ Ubiquigent"},{"orgOrder":0,"company":"Ubiquigent","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ubiquigent","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ubiquigent \/ Ubiquigent Limited","highestDevelopmentStatusID":"3","companyTruncated":"Ubiquigent \/ Ubiquigent Limited"},{"orgOrder":0,"company":"Ubiquigent","sponsor":"Nanna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ubiquigent","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ubiquigent \/ Nanna Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Ubiquigent \/ Nanna Therapeutics"},{"orgOrder":0,"company":"Ubiquigent","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Debio-0432","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ubiquigent","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ubiquigent \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Ubiquigent \/ Debiopharm"},{"orgOrder":0,"company":"Ubiquigent","sponsor":"Ubiquigent","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ubiquigent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ubiquigent \/ Ubiquigent","highestDevelopmentStatusID":"14","companyTruncated":"Ubiquigent \/ Ubiquigent"}]

    Find Clinical Drug Pipeline Developments & Deals by Ubiquigent

    Menu

    Ubiquigent

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ubiquigent

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ubiquigent

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Recipient : Alleo

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Alleo & Ubiquigent Partner on AI-Driven DUB-Focused Drug Discovery

                            Details : The partnership will combine Alleo’s AI-based approach to developing novel therapeutics with Ubiquigent’s platform and expertise in the field of DUB focused drug discovery.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 15, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Recipient : Alleo

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ubiquigent

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ubiquigent

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Debio-0432

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ubiquigent and Debiopharm Collaborate on USP1 Inhibitor Program for Debio 0432

                            Details : Ubiquigent will use its DUB-focused platform to develop novel target engagement assays supporting Debio-0432, a small molecule USP-1 inhibitor approaching clinical trials.

                            Brand Name : Debio-0432

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 26, 2024

                            Lead Product(s) : Debio-0432

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ubiquigent

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ubiquigent

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Nanna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ubiquigent Enters Agreement with Astellas Subsidiary, Nanna Therapeutics

                            Details : Ubiquigent will provide Nanna access to its deubiquitylase (DUB) platform to support novel therapeutics development for selected human disease targets.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 11, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Nanna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ubiquigent

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ubiquigent

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Ubiquigent Extends and Expands Drug Discovery Collaboration With Bristol Myers Squibb

                            Details : Under the terms of the agreement, Ubiquigent will provide Bristol Myers Squibb with increased access to its deubiquitylase (DUB) enzyme inhibitor drug discovery platform to provide further support to additional therapeutic areas.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 26, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ubiquigent

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ubiquigent

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Medivir

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Medivir Enters Into Licensing Agreement with Ubiquigent for Preclinical Program USP7

                            Details : Medivir has granted Ubiquigent an exclusive worldwide license to develop and commercialize the program including all associated compounds across any therapeutic indication(s) in return for agreed revenue share upon successful development or commercializa...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 10, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Medivir

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ubiquigent

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ubiquigent

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb

                            Details : The collaboration, originally between Ubiquigent and Celgene, will allow Bristol Myers Squibb to capitalise on the strength and breadth of Ubiquigent’s deubiquitylase (DUB) enzyme inhibitor drug discovery platform and expertise.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 17, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth